Predicting the future of human gene therapy for cardiovascular diseases: what will the management of coronary artery disease be like in 2005 and 2010?
Section snippets
Systemic risk factors
Probably the best-known example of gene therapy to treat inherited disease is in the treatment of familial homozygotic hypercholesterolemia (FHH). FHH is a monogenic genetic disease resulting from mutation of low-density lipoprotein (LDL) cholesterol receptors. Premature CAD mortality is a result of the rapidly ensuing atheroma precipitated by the presence of very high cholesterol levels that are unresponsive to conventional treatment with statins and other agents. Grossman et al2 reintroduced
Therapeutic angiogenesis
Gene therapy has an important application in enabling therapeutic concentrations of a gene product to be accumulated at the target site of action. It also offers the possibility of minimizing systemic side effects by avoiding high plasma levels of the gene product.
A number of small, mostly open-label phase 1 or 2 studies have been conducted with adenovirus- and plasmid-based vascular endothelial growth factor and fibroblast growth factor (FGF) gene constructs in CAD and peripheral vascular
Restenosis
Nitric oxide has a pleiotropic effect in that it causes vasodilatation, prevents proliferation and clotting, and acts as a scavenger of free radicals. Many animal models have demonstrated the therapeutic effect of this form of gene therapy,4 but it is difficult to apply these results to humans.
The use of endogenous or induced nitric oxide synthetase in rat carotid artery has produced promising results and, in a more recent study in pigs, induced nitric oxide synthetase administration via
Bypass graft failure
Arresting the cell cycle at the transition from the first gap period (G1) to the synthetic (S) phase provides an exciting opportunity for preventing graft failure. Quiescent (G0) cells enter G1, during which the factors necessary for DNA replication in the subsequent S phase are assembled. After DNA replication is completed, the cells enter another gap phase (G2) in preparation for mitosis (M).
The transition from G1 to S is a very important therapeutic target. This checkpoint is regulated by
Myocardial protection
Gene therapy is usually considered to be an acute intervention at the time of ischemia and/or reperfusion. However, problems lie in the delay in introducing the gene and the time for it to be transcribed, translated, and ultimately modified and released. Transfection efficiency also needs to be improved. Because of these difficulties, gene therapy for acute myocardial ischemia and/or reperfusion is unlikely to be a reality in the very near future.
Long-term use of gene therapy ahead of the event
Myocardial repair and regeneration
The goal of this form of therapy is to activate and mobilize cells for repair and reconstitution after an acute coronary event. Myocardial infarction (MI) leads to loss of tissue because of apoptotic and necrotic cell death. The remaining myocytes are unable to reconstitute the lost tissue, and the postinfarcted heart deteriorates functionally with time. Recent data suggest that progenitor cells originating from bone marrow can migrate to the site of damage and undergo differentiation, thereby
Conclusions
By 2005, it is likely that phase 3 studies in many of the areas discussed will be complete, but it is unlikely that these gene therapy applications will be used routinely in clinical practice because of the time taken for the regulatory process to be completed and for physicians to adopt the technologies in their daily practice.
However, we can predict that 5 years further on, in 2010, some of the studies will have resulted in products that are in regular clinical use. It is possible, for
References (14)
- et al.
Cardiovascular gene therapy
Lancet
(2000) - et al.
Ex-vivo gene therapy of human vascular bypass grafts with EF2 decoythe PREVENT single-centre, randomised, controlled trial
Lancet
(1999) - et al.
A pilot study of ex vivo gene therapy for homozygous familiar hypercholesterolemia
Nat Med
(1995) - et al.
Angiogenic gene therapy strategies for the treatment of cardiovascular disease
Curr Opin Mol Ther
(2002) - et al.
Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb—on the way to the clinic
Eur J Clin Invest
(2001) - et al.
Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation
Hum Gene Ther
(2003) - et al.
Vascular proliferation and atherosclerosisnew perspectives and therapeutic strategies
Nat Med
(2002)
Cited by (14)
Heme as key regulator of major mammalian cellular functions: Molecular, cellular, and pharmacological aspects
2006, Pharmacology and TherapeuticsInterleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis
2005, Laboratory InvestigationGene therapy and CVD: How near are we?
2004, Atherosclerosis SupplementsTargeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response
2014, Journal of Experimental MedicineMitochondria and their role in cardiovascular disease
2013, Mitochondria and Their Role in Cardiovascular Disease